CMAC (Continuous Manufacturing and Advanced Crystallisation), a research center focused on advanced pharmaceutical manufacturing, has announced its new partnership with Sanofi, a renowned global pharmaceutical company, as a Tier 1 member. 

Sanofi joins an esteemed consortium of eight Tier 1 partners within the global pharmaceutical industry, including AstraZeneca, Chiesi, Eli Lilly, Pfizer, Roche, Takeda, and UCB. As a Tier 1 partner, Sanofi will benefit from access to a wide range of resources, including state-of-the-art facilities, peer-to-peer knowledge exchange, PhD placements, mentorship opportunities, and the ability to contribute to pioneering research programs.

The expertise brought by Sanofi will further enhance CMAC's research portfolio, particularly in accelerating the implementation of CMAC Strategy and key research streams such as CCSa, MCS+b, BPCSc, and Quality by Digital Design (QbDD). Sanofi's commitment to Digital Transformation of CMC (Chemistry, Manufacturing, and Control) aligns seamlessly with CMAC's vision to revolutionize medicines manufacturing, promoting sustainability and innovation.

Massimo Bresciani, CMAC Industry Director, expressed his enthusiasm about the partnership, stating, “We are thrilled to welcome Sanofi to our esteemed roster of Tier 1 partners at CMAC. This exciting collaboration underpins our mutual dedication to innovation, propelling us towards a future where collective expertise drives significant industry breakthroughs.”

Robert Yule, Head of US Engineering and Modelling at Sanofi, emphasized the company's commitment to advancing pharmaceutical manufacturing through digital technologies. He stated, “Sanofi looks forward to working with CMAC to advance the use of Digital Twins and promote continuous manufacturing with the goal of producing lower-cost drugs that have more eco-friendly manufacturing processes.”

The partnership between CMAC and Sanofi holds promise for driving advancements in pharmaceutical manufacturing processes, ultimately benefitting patients worldwide with improved access to high-quality, cost-effective medications.